Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235

Revolution Medicines

Revolution Medicines

RVMD

0.00

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ: RVMD) with a Buy and raises the price target from $205 to $235.